Immupharma Share Discussion Threads

[cammy5] 01/1/2018 18:05

Ye I think your right ,if it hits £2.50 I think I'll sell half and move on to pastures new and , it's a freebie with the balance I have left . Cheers

[bookbroker] 01/1/2018 17:38

Just hold, u are in profit, it will not collapse even if the placebo pretences to be as effective as Lupozor, peptides have many uses in medicine apart from this one(der) drug! It’ll be a blow, but not a killer, we are thus far down the line!

[barriew] 01/1/2018 17:31

Why not sell a few, put in something else.
If results are good, you will be rewarded anyway,
If they are bad the nucant and other technologies are worth the 70 p.

But i expect results as ph 2 or better.

[cammy5] 01/1/2018 16:35

Some people on this board are freaking me out , bought in on an average of70p if it rises much more ,don't no if I have the nerve to hold

[hitsha1] 01/1/2018 13:31

I think we will be £5-7 next two weeks, it’s all about momentum, supply demand,

[hottingup] 01/1/2018 13:18

In Mar 2009, HGSi shares (on their 50% stake in lupus drug Benlysta) were $0.45, becoming $3.23 (market cap $528m) early Jul 2009 just before PIII Benlysta results, $12.51 (market cap of $2 billion+) at close on results day late Jul 2009, and $34.49 ($6.46 billion market cap, as there was also some dilution) at peak in Apr 2010 = 76x return over 13 months from peak low to peak high. (Source: Poster 'sicilian_kan', L-S-E, 8/7/2017)


Not bad on a 50% stake in a drug that seems to be less efficaceous and safe, and more expensive to make, than IMM's Lupuzor; and is just one drug, not one drug within an entire platform applicable to at least 12 big market indications, like Lupuzor.

[hottingup] 01/1/2018 13:18

Shares Magazine
Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"Drug developer ImmuPharma (IMM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."


This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.


Tim McCarthy (IMM Chairman)
14/3/2017
"There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug."

4 min 40 sec.

[postbrexit1] 01/1/2018 12:25

Any predictions as to final price prior to the trial results being announced (subject to any leaks?) in jan.My estimate is probably £2.10 to 2.30.Interesting to hear other views.

[top tips] 01/1/2018 10:56

Yes for a second or two on the way to somewhere higher.

[jpleight] 01/1/2018 10:53

will the price reach 200 after the next rns?

[kensingtoncourt] 01/1/2018 10:30

Don't stress yourself guys. If the results are good they have a multi blockbuster product and it will find its own high level once the bidding war starts.

[money maker1] 01/1/2018 10:25

I just analyse the facts and it genuinely produces a higher range price.

[talkman2] 01/1/2018 10:03

These fanciful prices are ridiculous. You are probably looking at around £10 to £20 if all things go to plan . People have got to be sensible and realistic.

[money maker1] 01/1/2018 09:27

To value Lupuzor you have to value the whole platform, new patent and its likely multi billion $ sales, possibly replicated in several indications. Hence £60 to £100.

[greatfull dead] 01/1/2018 08:16

My New Years resolution. Do your own research and follow your own instincts from you research findings.

Happy New Year All, even to those here who like to play pointless hand bag fights.

GD

[runtoma] 01/1/2018 07:49

Hi Nyboy I only need one this one and through it I can say all I want to say The only reason I joined was because of deramper njb67. Once he goes I will go and I will only come back if he does in disguise (him not me) I am not interested in joining in your day to day posts. Although, I will read what you say. As far as I am concerned immupharma needs no ramping. The science, the directors and broker speak for it and anything you all say here does not really add to that. I don't know what gave you the idea that I have multiple user names.I don't see anyone who writes like I do and any technical type comments would be beyond me and I find boring.Are you really njb67?

[ny boy] 01/1/2018 03:20

Stop making up multiple user names, it’s getting a tad tiring....


runtoma
Member since: 30 Dec 2017

[hottingup] 31/12/2017 23:57

Have a good New Year people. IMM value looks to be well over £40.

[bermudashorts] 31/12/2017 19:12

"I hope the news is good not only for our financial well being but for all the patients of Lupus and other indications that can benefit from this drug"

Well said Nigsrodders

[nigsrodders] 31/12/2017 18:53

BM, I guess your 8298 was offensive because deficient in the constant repetition of arithmetic compounding of patients treated to arrive at a squillion pound revenue and a market cap equating to 37th constituent of FTSE 100.
Not many days to discover the fundamentals of Lupuzor effectiveness. I hope the news is good not only for our financial well being but for all the patients of Lupus and other indications that can benefit from this drug.
A Happy New Year to all of you, both added value and populist posters.

[runtoma] 31/12/2017 16:34

I hope you mean that

[ewads] 31/12/2017 16:28

runtoma - only joking!

[hamhamham1] 31/12/2017 16:26

Christ you lot are a bunch of planks.
Unbelievable, acting like a bunch of 5 year olds in the playground.
Life's too short.
See you on results day.

[englishlongbow] 31/12/2017 16:07

Njb67 is a nupty with an agenda. He will no doubt be eager for his next oap's payment and saving up for his next big £50 investment and a bumper pack of incontinence pads.

[runtoma] 31/12/2017 15:52

To be fair I will second ewads post. There have been some good objective points raised by njb67. The point he raised about the cost of refrigerated trucks was worrisome What about Mauritius? There may be a shortage of refrigerated trucks. Will Lupizor be transported in an ice cream van! Also his novel way of investing. Buy shares and then relentlessly talk it down. Whose to say it does not work? It is like head transplant surgery.Something completely new. njb67 could very well be a trailblazer